[Malignant transformation of mouse embryo cells by estrogenic hormones in vitro].
Mouse embryo cells (MEC) taken from a LACA pregnant female mouse, were cultured in RPMI 1640 medium with 20% horse serum. In the experimental group (10 bottles), the first 3 generations of MEC were treated with estradiol valerate (E) and hydroxyprogesterone caproate (P) at doses of 5.2 micrograms/ml and 261 micrograms/ml medium in the original and the 2nd generations, and at double doses in the 1st generation. In the control group (10 bottles), the MEC were cultured without E and P. The MEC in both groups was subdivided into 3 bottles from 1 every seven days. In the experimental group (44 bottles), the morphological transformation emerged in 2 bottles of MEC (the 5th and 7th generations) after 79 day's treatment by E and P. Meanwhile, the nonmorphological transformed cells (the 3rd, 5th and 7th generations) had the ability to grow in ouabain-contained medium (Anti-Oua+). It implies that the mutation had already occurred before transformation. The transformed cells had the ability to form colonies in soft-agar medium, could be agglutinated by concanavalin A and form fibrosarcoma in the subcutaneous region after inoculation. Basing on the above results, we suggest that E and P directly act as a carcinogen on the MEC and cause the latter to undergo malignant transformation.
D000077713:17 alpha-Hydroxyprogesterone Caproate; D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D002478:Cells, Cultured; D004622:Embryo, Mammalian; D004958:Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives; D004967:Estrogens / Q000009:adverse effects*; D004966:Estrogens, Conjugated (USP); D005260:Female; D006908:Hydroxyprogesterones / Q000009:adverse effects; D051379:Mice; D045167:Progesterone Congeners / Q000009:adverse effects
D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D006908:Hydroxyprogesterones; D045167:Progesterone Congeners; D000077713:17 alpha-Hydroxyprogesterone Caproate; D004958:Estradiol